Nelson et al,

I expect some of the whole virus vaccines to gain a foothold, should they prove effective in trials.

They should elector a broader range of antibodies than antibodies specific to one spike protein conformation.

There is a potential that these could be effective against infection, not just severe disease manifestations.

Leronlimab of course may very well rule the roost after successful Brazilian and LH trials.